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Abstract
Hepatitis C Virus (HCV) is a major public health concern, with no effective vaccines currently available and 3% of the world’s
population being infected. Despite the existence of both B- and T-cell immunity in HCV-infected patients, chronic viral
infection and HCV-related malignancies progress. Here we report the identification of a novel HCV TCR from an HLA-A2-
restricted, HCV NS3:1073–1081-reactive CTL clone isolated from a patient with chronic HCV infection. We characterized this
HCV TCR by expressing it in human T cells and analyzed the function of the resulting HCV TCR-transduced cells. Our results
indicate that both the HCV TCR-transduced CD4
+ and CD8
+ T cells recognized the HCV NS3:1073–1081 peptide-loaded
targets and HCV
+ hepatocellular carcinoma cells (HCC) in a polyfunctional manner with cytokine (IFN-c, IL-2, and TNF-a)
production as well as cytotoxicity. Tumor cell recognition by HCV TCR transduced CD8
2 Jurkat cells and CD4
+ PBL-derived T
cells indicated this TCR was CD8-independent, a property consistent with other high affinity TCRs. HCV TCR-transduced T
cells may be promising for the treatment of patients with chronic HCV infections.
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Introduction
Hepatitis C Virus (HCV) infection is a major public health
concern with approximately 3% of the world’s population being
infected [1]. Unfortunately, 70–80% of infected individuals are
unable to clear the virus, resulting in a chronic infection with the
potential for developing severe liver diseases such as cirrhosis and
hepatocellular carcinoma (HCC) [2,3]. These liver diseases are the
major indication for liver transplantation in the US and Europe
[4,5]. The combination therapy of interferon-a and ribavirin is
used to treat HCV infections with limited success [6]. The
development of preventative and therapeutic vaccines has been
hindered by a lack of relevant animal models to study HCV viral
replication and disease progression in vivo.
Both cellular and humoral immunity exists against HCV
proteins in HCV-infected individuals [7]. However, not all
HCV-infected patients can mount an effective anti-HCV immune
response leading to the reduction of the viral load [8,9]. There is
evidence that demonstrates that the HCV genome mutates rapidly
suggesting that mutations in T-cell and B-cell epitopes lead to
immune escape variants which may be the main reason for HCV
persistence in chronically infected patients [10–12]. Therefore,
until better immune-based strategies are developed, immune
therapy will have limited benefit for HCV-infected patients.
An approach has been described in which retroviral vectors
encoding T-cell receptor (TCR) genes are used to redirect the
specificity of normal peripheralblood lymphocyte (PBL)-derived T cells
to recognize the melanoma associated antigen, MART-1 [13,14].
Subsequently, this approach has been extended to other tumor
antigens and viruses [15–28]. In fact, three phase I/II clinical trials
using this approach to treat melanoma have been reported [29–31]. In
two of these studies, no serious adverse events were observed and a few
objective clinical responses were reported [29,30]. However, the third
s t u d yr e p o r t e da ni n c r e a s ei nt h ef r equency of clinical responses but a
few patients experienced adverse events [31]. With TCR gene transfer
becoming a reality for cancer patients, it opens the possibility for
engineering a patient’s own T cells to recognize their HCV virus-
infected cells, regardless of their immune status.
It has also been well known that the HCV genome contains
several regions and it is genetically unstable and mutates readily.
The high variation of HCV is used to produce escape mutants that
can sneak past the immune response of the host. The variants also
play a significant role in the progression of virus infection due to
resistance to immunotherapy. We have previously identified HCV
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[24,32]. In the current study, we cloned novel HCV TCR genes
from an HLA-A2-restricted, HCV NS3:1073–1081-reactive, T-
cell clone isolated from a patient with chronic HCV infection. This
is an important epitope since it is frequently the immunodominant
epitope targeted by anti-HCV CTL in HCV infected patients
[33]. It also shares sequence homology with a peptide from the
influenza A virus and CTL have been shown to crossreact with
both peptides [34]. And finally, it is often mutated in HCV
immune escape variants making it likely to be an important target
in the anti-HCV immune response [35]. For the first time, we
demonstrate that a recombinant retroviral vector encoding the
HCV NS3:1073–1081 TCR could efficiently transduced both
CD4
+ and CD8
+ T cells. Functional analysis demonstrates that the
HCV TCR-transduced both CD4
+ and CD8
+ T cells produce
interferon-c, TNF-a, and to a lesser extent, IL-2 when stimulated
with the peptide-loaded targets or HCV
+ hepatoma cells. Our
results indicate that an HCV TCR can engineer antigen reactive
CD4
+ and CD8
+ T cells, raising the possibility that we can provide
any HCV patient with a source of autologous HCV-reactive T
effector and helper cells which have been implicated in eradicating
HCV infections.
Results
Identification of the TCR Genes Used by an HCV Reactive
T Cell Clone
An HCV NS3:1073–1081-reactive CTL clone was isolated
from the blood of a patient with a chronic HCV infection by
limiting dilution cloning. The T cell clone was analyzed for
antigen recognition in cytokine release assays. As shown in
Figure 1, the T cell clone secreted significant amounts of
interferon-c when stimulated with T2 cells loaded with the
HCV NS3:1073–1081 peptide but not the control CMVpp65 or
HCV NS3:1406–1415 peptides. These results indicate that the T
cells isolated from the patient with a chronic HCV infection were
reactive with the HCV NS3:1073–1081 antigen.
The HCV NS3:1073–1081 TCR a and b chains from the HCV
NS3:1073–1081-reactive, T cell clone were identified as described
[36]. The germline V genes, J regions, and the unique CDR3
region sequences for each TCR chain are shown in Figure 2. DNA
sequence analysis of random 59 RACE TCR a chain cDNA clones
revealed the HCV NS3:1073–1081 T cell clone expressed a single
TCR a chain consisting of AV20s1/AJ10/AC. This TCR a chain
was in-frame and contained all of the landmarks consistent with a
functional TCR a chain. The TCR b chain was identified by RT-
PCR using a panel of TCR BV subfamily specific primers as
described [37]. The only primer that amplified a fragment of the
predicted size was the BV13 primer suggesting that the TCR
expressed by the HCV NS3:1073–1081 reactive T cell clone used
member of the BV13 subfamily (data not shown). DNA sequence
analysis of that PCR fragment revealed that the TCR b chain
consisted of BV13s6/BJ2s1/BJ2s7/BC2. Like the TCR a chain,
the DNA sequence of the TCR b chain indicated it was in-frame
and contained all of the features consistent with a functional TCR
b chain. The identification of the TCR b chain being BV13 was
confirmed by immunofluorescence staining with an anti-Vb13s6
mAb (data not shown). Thus, the HCV NS3:1073–1081 T cell
clone expresses an AV20s1/BV13s6 TCR.
Construction of an HLA-A2
+ HCC Cell Line Expressing the
HCV NS3:1073–1081 Epitope
The critical feature for a TCR gene-modified T cell is its ability
to recognize endogenous antigen on the target-cell surface.
However, human liver or HCC cells infected with HCV were
not available for our experiments. Therefore, we established an
HCV expressing HCC cell line to test the ability of our TCR-
transduced T cells to recognize HCV
+ liver tumor cells. An HCV
expression construct was prepared by fusing the HCV NS3:1073–
1081 minigene to the EGFP gene which was used as a marker to
monitor the level of antigen expression by the HCC cells. The
HCV/EGFP fusion construct was inserted into the retroviral
vector pMFG (Figure 3A) which was used to transduce the HLA-
A2
+ hepatocellular carcinoma cell line, HepG2 (HLA-A2
expression is shown in Figure S1). HCV minigene-positive cells
were defined by their EGFP expression as measured by flow
cytometry (Figure 3B) and EGFP expressing cells were sorted by
FACS for high and homogeneous antigen expression. The HCV
+
HCC cells were then used as stimulators in cytokine release assays
to evaluate the function of HCV TCR transduced T cells.
HCV NS3:1073–1081 Antigen Recognition by HCV TCR-
Transduced Jurkat Cells
We have generated the recombinant retroviral construct
containing the TCR a and b chains of the HCV NS3:1073–
1081 reactive T cell clone (Figure 4). To verify the expression and
function of this cloned TCR, we used this retroviral vector to
transduce Jurkat 76 cells. Jurkat 76 cells are a TCR a
2 and b
2
derivative of the CD8
2 human T cell lymphoma Jurkat cell line.
Since Jurkat 76 cells are TCR negative, any introduced TCR
would not have to compete with the endogenous TCR and its
expression can be monitored by staining with anti-CD3 mAb.
Furthermore, Jurkat 76 cells expressing a cloned TCR secrete IL-2
upon antigen stimulation in an antigen-specific fashion. Therefore,
Jurkat 76 cells are an excellent model to evaluate the expression
and function of any cloned TCR. As shown in Figure 5A, Jurkat
76 cells expressing the HCV NS3:1073–1081 TCR stained with
anti-Vb13.6 and anti-CD3 mAb’s indicating the TCR could
assemble on the surface of the Jurkat 76 cells. When stimulated
with antigen, these HCV TCR transduced Jurkat 76 cells secreted
significant IL-2 in response to T2 cells loaded with the HCV
NS3:1073–1081 peptide but not T2 cells alone or T2 cells loaded
with the CMV pp65:495–503 peptide (Figure 5B). The HCV
TCR transduced Jurkat 76 cells also recognized HepG2 cells
loaded with the HCV NS3:1073–1081 peptide or transfected to
express the HCV NS3:1073–1081 epitope. It should be noted that
Author Summary
Hepatitis C Virus (HCV) is a major public health concern
with a large number of individuals infected (3% world
wide). Currently, there is no effective vaccine available to
prevent HCV infection and the treatment is effective in less
than half of all patients. Therefore, many patients have
long term infections that lead to severe liver damage or
liver cancer. It has been shown that some HCV infected
patients can eliminate the virus and the host immune
system is involved. The problem is most people do not
have the capacity to fight their HCV infection. We have
developed a gene therapy based approach where a
patient’s own immune cells can be made to recognize
cells expressing HCV genes. This can be accomplished
regardless of his or her natural capacity to fight their HCV
infection. This manuscript describes how normal immune
cells can be genetically altered to recognize cells
expressing HCV proteins and characterizes their reactivity
and sensitivity to antigen stimulation.
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(Figure 3B), they were not recognized by the Jurkat cells expressing
the HCV TCR. More importantly, recognition of HCV
+ HepG2
cells by CD8
2 Jurkat cells indicates our HCV TCR transfers CD8
independent tumor cell recognition to alternate effectors. These
results indicate the HCV TCR is functional and has high affinity
for antigen.
Recognition of HCV
+ Hepatocellular Carcinoma Cells by
the HCV TCR-Transduced T Cells
Although Jurkat 76 cells are a good model cell line for verifying
the function of a cloned TCR, they can’t be used in preclinical
animal studies or clinical trials to control HCV infections or the
growth of HCV
+ HCC cells. Therefore, it is critical to evaluate the
function of normal PBL-derived T cells expressing our HCV
TCR, particularly with regards to their ability to recognize a
physiologically relevant target such as hepatocellular carcinoma
cells. To accomplish this goal, we generated populations of HCV
TCR transduced PBL-derived T cells from a total of seven normal
healthy donors. The level of expression and the percent HCV
TCR transduced T cells was measured by anti-Vb13.6 mAb
staining. The results from a typical HCV TCR transduced T cell
culture is shown in Figure 6A. Compared to the isotype control,
mock transduced T cells contained 1.1% Vb13.6 staining cells.
Figure 1. Antigen recognition by HCV T-cell clone 1073. The specificity of HCV-reactive T cell clones was assessed using interferon-c release
assays. T2 cells were incubated for 2 hr with 5 mg/ml of HCV NS3 1073–1081, HCV NS3:1406–1415, or CMVpp65 peptide. Peptide-loaded T2 cells were
incubated for 20 hr in microwells with the HCV T cell clone 1073 (white bars). As a specificity control, an HCV NS3:1406–1415 T cell clone (black bars)
was included in the assay. The amount of interferon-c produced was measured by ELISA.
doi:10.1371/journal.ppat.1001018.g001
Figure 2. Junctional sequences of the TCR a chain and the TCR b chain identified from HCV NS3:1073–1081 clone. TCR analysis
revealed that the HCV NS3:1073–1081 clone expressed a single TCR a chain (AV20s1) and a single TCR b chain (BV13s6). The germline V genes and J
regions (and D region for the b chain) are shown for each TCR chain. The unique N regions in the CDR3 region of each chain are listed.
doi:10.1371/journal.ppat.1001018.g002
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normal PBL. The HCV TCR transduced T cell cultures contain
36% Vb13.6 staining cells with the level of TCR expression being
variable as expected by a TCR-transduced T cell population.
These results indicate that our HCV TCR can be efficiently
expressed by PBL-derived T cells from normal donors. However,
despite having anywhere from 20%–40% Vb13 expressing T cells
in the HCV TCR transduced T cell cultures, only about 0.25% of
the CD4
+ and CD8
+ T cells bind HCV 1073 peptide loaded
pentamers (Figure S2). We and others have found that tetramer
binding does not always correlate with TCR expression and
function so this result was not surprising [38–40].
PBL-derived T cells from the normal donors were transduced
with our HCV TCR and assessed for their ability to recognize
antigen. Using a combination of cytokine release and intracellular
cytokine staining, we evaluated the antigen reactivity of each of the
HCV TCR transduced T cell cultures. All of the bulk T cell
cultures produced significant amounts of interferon-c when
stimulated with T2 cells loaded with the HCV NS3:1073–1081
peptide but not T2 cells alone or T2 cells loaded with the control
Figure 3. HCV NS3:1073–1081 expression in the hepatocellular carcinoma cell line HepG2. The HLA-A2
+ HepG2 hepatocellular carcinoma
cell line was transduced with the MFG retroviral vector encoding a fusion protein consisting of a the HCV NS3:1073–1081 peptide sequence fused in-
frame with EGFP. (A) HCV NS3 1073–1801 minigene coding sequence fused to EGFP was inserted into a retrovirus vector pMFG. (B) HepG2 cells were
transduced with pMFG EGFP or pMFG-HCV1073/EGFP. Transduced cells were enriched for uniform high antigen expression by FACS sorting based on
EGFP expression. Open curves in each histogram represent transduced HepG2 cells (mock or HCV 1073 vevtor) while shaded curves represent
untransduced cells. Each histogram represents the log green fluorescence of 1610
5 live cells as measured by flow cytometry.
doi:10.1371/journal.ppat.1001018.g003
Figure 4. Structure of retroviral vectors used for TCR gene transfer and TCR expression on transduced cells. A modified SAMEN
retroviral backbone was used for transferring TCR genes to alternate effectors. The retroviral vector contains the HCV TCR 1073 a and b chain genes
fused by a 2A self cleavage peptide, under control of the hybrid MMLV/CMV promoter in the 59 LTR. An IRES/neo cassette was included for G418
selection of transduced cells.
doi:10.1371/journal.ppat.1001018.g004
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These HCV TCR transduced T cells did produce TNF-a and IL-
2 upon stimulation with peptide loaded T2 cells (Figure 7 and
Figure S3). The HCV TCR transduced bulk T cells also efficiently
recognized HepG2 cells (which naturally express HLA-A2; Figure
S1) loaded with HCV NS3:1073–1081 peptide or transfected to
express the HCV NS3:1073–1081 epitope (Figure 6 and Figure
S3). It should be noted that despite the mock transfectants having
higher expression of EGFP (Figure 3B), they were not recognized
by the normal PBL-derived T cells expressing the HCV TCR.
Moreover, TCR-transduced PBL demonstrated cytotoxicity as
shown by the production of CD107a (Figure 8). Therefore, our
HCV TCR efficiently engineers normal PBL-derived T cells to
recognize HCV peptide loaded targets with a polyfunctional
response (production of IFN-c, IL-2, TNF-a and CD107a).
Recognition of peptide loaded targets by HCV TCR-trans-
duced T cells confirms the reactivity of our HCV TCR in normal
PBL-derived T cells. However, it is more important to verify the
Figure 5. Expression and Function of the HCV TCR in Jurkat 76 cells. Jurkat 76 cells were transduced with the HCV TCR retroviral vector. (A)
Expression of the HCV TCR in transduced Jurkat 76 cells was measured by CD3 and Vb13.3 expression. Jurkat 76 cells were stained with anti-CD3 and
anti-Vb13.6 antibodies. Left panel: isotype control staining; right panel: anti-CD3 and anti-Vb13.6 mAb staining. (B) Antigen recognition by HCV 1073
TCR transduced Jurkat cells was measured using IL-2 release assays. T2 or HepG2 cells were pulsed for 2 hr with 5 mg/ml of HCV NS3 1073–1081
peptide or CMVpp65 peptide. Peptide loaded cells or HCV
+ HepG2 cells were incubated for 20 hr in microwells with the HCV TCR 1073 tranduced
Jurkat 76 cells. The IL-2 production was measured by ELISA.
doi:10.1371/journal.ppat.1001018.g005
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+ cells such as HCC cells.
The recognition of HCV
+ HepG2 cells by the HCV TCR
transduced Jurkat 76 cells indicated that our HCV TCR transfers
CD8-independent tumor cell recognition to alternate effectors
(Figure 5B). We have previously reported that CD8 independent
TCR’s are capable of generating MHC class I restricted CD4
+ T
cells making it possible to provide patients with a novel source of T
cell help [41,42]. To determine if our HCV TCR can generate
MHC class I restricted CD8
+ effector and CD4
+ helper T cells, we
transduced PBLs derived T cells from three healthy donors and
purified the CD4
+ and CD8
+ T cells to greater than 99% purity
using immunomagnetic beads to measure cytokine production by
ELISA (Figure 6 and Figure S3) or analyzed each subset for
intracellular cytokine production or CD107a expression (Figure 7
and Figure 8). CD4
+ and CD8
+ T cells, transduced to express our
HCV TCR, produced significant amounts of interferon-c, TNF-a,
IL-2, and CD107a when stimulated with HCV peptide loaded T2
cells or HepG2 cells but not controls. Importantly, the HCV
TCR-transduced CD4
+ T cells secreted significant amounts of
cytokine when stimulated with HCV
+ tumor cells. These results
Figure 6. Antigen recognition by HCV TCR 1073-transduced PBLs. (A) Expression of HCV 1073 TCR on transduced PBLs. PBLs from three
representative normal donors (Donors 1–3) were transduced with the HCV 1073 TCR retroviral vector. TCR-transduced cells and mock transduced T
cells were stained with anti-Vb13.6mAb. Solid gray: isotype control; Open white: anti-Vb13.6mAb; left panel: mock vector transduced cells, right
panel: TCR transduced cells. (B) Antigen recognition by HCV TCR 1073-transduced T cells. T2 cells or HepG2 cells were pulsed for 2 hr with 5 mg/ml of
HCV NS3 1073–1081 peptide or CMVpp65 peptide. Peptide-pulsed T2 cells, HepG2 cells and HCV
+ HepG2 cells were incubated for 20 hr in microwells
with the HCV TCR 1073 T cells. The interferon-c production was measured by ELISA.
doi:10.1371/journal.ppat.1001018.g006
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and 5) were stimulated with T2 cells loaded with the cognate HCV 1073 peptide or the control HCV 132 peptide and stained for intracellular IFN-c
(Y-axis), IL-2 (X-axis, top row), and TNF-a (X-axis, bottom row). The amount of fluorescence was measured by flow cytometry and each histogram
represent 10
4 cells.
doi:10.1371/journal.ppat.1001018.g007
Figure 8. CD107a staining of HCV TCR 1073-transduced T cells. HCV TCR1073 transduced T cells were stimulated for 20 hours with peptide
loaded T2 cells or HepG2 tumor cells. T2 cells were pulsed for 2 hr with 5 mg/ml of the HCV NS3 1073–1081 peptide or the CMV pp65 control peptide.
Parental HepG2 tumor cells or HCV
+ HepG2 cells were used as stimulators. Following the stimulation, the T cells were collected and stained with anti-
CD107a mAb. Cells were gated on CD3
+ fraction and the numbers in the quadrants represent the percentage of either CD4
+ or CD8
+ cells staining for
CD107a expression. The amount of fluorescence was measured by flow cytometry and each histogram represent 10
4 cells.
doi:10.1371/journal.ppat.1001018.g008
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+ T cells and
CD4
+ T cells to recognize HCV
+ cells. Also, our ability to generate
MHC class I restricted CD4
+ T cells raises the possibility that we
can provide any HCV patient with a source of autologous HCV-
reactive T helper cells which has been implicated in eradicating
HCV infections [43].
Relative Functional Avidity of HCV TCR-Transduced T
Cells
It has been shown that there is a correlation between the
functional avidity of a T cell and its ability to recognize tumor cells
or virus-infected cells [43–47]. Furthermore, T cells expressing a
high affinity TCR have been shown to be exquisitely sensitive to
low levels of antigen [48]. T cells with identical specificities, but
different functional avidities, influence each other during activa-
tion and homeostatic proliferation [49]. T cells exhibiting
increased sensitivity to stimulation, or a lower threshold, are said
to have a relatively high functional avidity [44–47]. T-cell
responsiveness to peptide is commonly used as a measure of T
cell avidity as it provides a measure of the stimulation threshold
required to activate T cell effector functions. Relative avidities
were evaluated by measuring T-cell interferon-c production. To
test the avidity of the HCV TCR-transduced T cells, we loaded
different peptide concentrations on T2 or HepG2 cells and
incubated with HCV TCR transduced T cells. The ability of the
transduced T cells to produce interferon-c was measured under
conditions of increasing concentrations of peptide stimulation. As
shown in Figure 9, the two representative HCV TCR transduced
T cell cultures (Donors 4 and 5) had high avidity for antigen since
they secreted significant amounts of interferon-c when stimulated
T2 cells loaded with 5 nM or less of peptide. Similar results were
found with three other HCV TCR transduced T cells cultures
(Donors 1–3) with the functional avidity of the HCV TCR
transduced T cells being approximately half a log lower than the
parent T cell clone (,1.0 vs ,0.5 nM) (Figure S4).
In contrast, Peptide loaded HepG2 cells were not recognized as
well as the T2 cells since it required between 50–500 nM peptide
to stimulate the HCV TCR transduced T cells. This was not
surprising since our HepG2 cells but not our T2 cells have their
MHC class I molecules loaded with peptides requiring peptide
exchange on the HepG2 cells for T cell recognition to occur. In
fact, the HCV TCR transduced T cells did not recognize the
HepG2 cells loaded with 5 mM peptide as well as the HepG2 cells
expressing the HCV 1073 minigene (576/345 pg/ml vs 717/
418 pg/ml respectively for donors 1 and 2) further supporting the
notion that exogenous peptide loading was less efficient than
endogenous peptide loading. Compared to other published
studies, our functional avidity measurements using peptide loaded
T2 cells indicate our HCV TCR transduced T cells have relatively
high avidity for antigen.
Discussion
The relationship between T cell avidity and the clearance of
viral infections and tumor cells has been well documented [44,45].
Many studies have been directed at elucidating the relationship
between T-cell activity and TCR affinity, dissociation rate, and
CD8
+ dependence. CD8
+ played an essential role in T-cell
recognition of low-affinity T-cell reactions [48]. However, we
speculated that any TCR that can bind peptide/MHC complexes
without CD8 would have higher relative affinity than a TCR that
requires CD8
+ for binding. To date, only a limited number of
CD8-independent TCRs have been cloned and characterized
[50]. The novel HCV TCR described herein exhibits CD8-
independent target cell-recognition since the HCV TCR-trans-
duced CD4
+ T cells could secret interferon-c and IL-2 when
stimulated with peptide-loaded targets or HCV
+ HCC cells
(Figure 6B and Figure S3). Based on this study, we conclude that
the affinity of this HCV TCR is higher than other TCRs that
require the CD8 coreceptor for target-cell recognition, These
results indicate that T cells isolated from patients with chronic
HCV infection can have high affinity TCRs and these TCRs may
be important for developing novel TCR-based gene therapy
studies. Thus, we have identified another high affinity TCR that
could be used to engineer normal PBL-derived T cells for clinical
application.
CD4
+ T cells are thought to contribute to anti-viral immune
responses by secreting cytokines, thereby providing help to CD8
+
T cells [51,52]. Antigens are taken up by antigen presenting cells
which may activate CD4
+ T cells to secrete either Th1 or Th2
cytokines. By producing Th1-cytokines like interferon-c and IL-2
CD4
+ T cells contribute to anti-viral immune responses providing
help to CD8
+ T and B cells. Furthermore, CD4
+ T cell lines and
clones can display direct cytotoxic effector function [51,52]. The
identified HCV TCR has been successfully transduced into CD4
+
T cells and these TCR-transduced CD4
+ T cells may not only
provide help to CD8
+ T cells, but also directly act on the HCV
+
target cells such as HCV-infected cells and HCV
+ HCC cells. This
is especially important for clearing HCV infection because one of
the fundamental problems typical of chronic HCV infection is a
weak or absent HCV- specific CD4
+ T-cell response [43,53].
The instability of the HCV genome makes the identification of
this high affinity HCV NS3:1073–1081 TCR particularly
important. We and others have previously shown that T cells
can express two functional TCRs capable of recognizing both
target antigens [54–56]. Therefore, when combined with our
previously identified HCV NS3:1406–1415 TCR, T cells
expressing both TCRs might be effective against HCV immune
escape variants for treatment of HCV-associated diseases.
Adoptive transfer of HCV TCR-transduced T cells may show
promise as a new treatment for patients with chronic HCV
infection or HCV-related malignancies, particularly in light of the
recent demonstration that HCC express HCV antigens [57].
Materials and Methods
Cell Lines, Media, and Reagents
T2 and HepG2 cells were obtained from the American Type
Culture Collection (Rockford, MD). The TCR-negative Jurkat 76
cell line has been described elsewhere [58]. Unless otherwise
indicates, All medium components were obtained from Mediatech
(Herndon, VA) unless otherwise noted. Jurkat 76 and T2 cell lines
were maintained in complete medium consisting of RPMI 1640
medium supplemented with 10% fetal bovine serum (Tissue
Culture Biologicals, CA) 100 U/mL penicillin, 100 mg/mL
streptomycin. Plat-A cells [59,60] and HepG2 cells were
maintained in Eagle’s medium supplemented as described above.
TCR-transduced Jurkat 76 cells were maintained in RPMI
medium as described above supplemented with 2 mg/mL G418.
To engineer tumor cell lines to express HCV sequences, we first
inserted synthetic oligonucleotides encoding the HCV NS3:1073–
1031 epitope into the retroviral vector, pMFG-EGFP. Briefly,
oligonucleotides encoding the HCV NS3:1073–1031 epitope and
containing mutated Nco I restriction sites (forward: 59-catgTG-
CATCAATGGGGTATGCTGGACTGTCgctgcttatgg-39; reverse
59- ccataagcagcGACAGTCCAGCATACCCCATTGATGCAcatg-
39) were synthesized and annealed. The underlined base pairs
indicate the overhang for the ligation of the double stranded
Transduction of T Cells with HCV-Specific TCR
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ligation strategy as described [41]. The recombinant vector was
transiently transfected into Plat-A packaging cells and the
retrovirus containing supernatant was collected for transduction
of HepG2 cells. The expression of the HCV NS3:1073–1081
minigine in the transduced HepG2 cells was confirmed based on
the EGFP expression as measured by flow cytometry. The EGFP
positive cells were sorted for high and uniform expression and the
resulting HCV
+ HCC cell line was established.
T Cells
All T cells were maintained in AIM V medium (Invitrogen,
GIBCO) supplemented with 5% heat-inactivated pooled human
AB serum (Valley Biomedical, Inc), 100 U/mL penicillin, 100 mg/
Figure 9. Functional avidity of HCV TCR 1073-transduced T cells. The functional avidity of HCV TCR transduced PBL-derived T cell cultures
was measured interferon-c release assays. T2 cells (Panel A) or HepG2 cells (Panel B) were loaded for 2 hr with varied concentrations of HCV NS3
1073–1081 peptide (0.05–5,000 nM). These peptide-loaded T2 or HepG2 cells were cocultured for 20 hr in microwells with two representative HCV
TCR transduced T cell cultures (Donors 4 and 5) and the amount of interferon-c produced was measured by ELISA. Background levels of interferon-c
produced when the T cells were cocultured with T2 cells alone or HepG2 cells were 38/0 (Donor 4) and 58/6 (Donor 5). The amount of interferon-c
produced when the T cells were cocultured with HepG2 cells expressing the HCV 1073 minigene was 717 and 418 (Donors 4 and 5 respectively).
doi:10.1371/journal.ppat.1001018.g009
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(rhIL-2; Novartis Pharmaceuticals Corporation, East Hanover,
NJ) at 37uC in a humidified 5% CO2 incubator. The isolation and
characterization of HCV-reactive T-cell clones has been previ-
ously described [32]. The HCV NS3:1073–1081-reactive CD8
+
T-cell clone used in this study was isolated from a patient with a
chronic HCV infection.. All PBMC used in this study came from
apheresis products purchased from (Research Blood Components,
L.L.C., MA). Normal PBL-derived T cells were isolated from the
PBMC cells of three independent normal healthy donors using
Ficoll-Hypaque density gradient centrifugation. The HCV T cell
clone and the TCR-transduced T cells were expanded using
30 ng/mL anti-CD3 monoclonal antibody (Ortho Biotech,
Raritan, NJ) and 300 IU/mL rhIL-2 in the presence of irradiated
pooled allogeneic peripheral blood mononuclear cells as feeders as
previously described [61].
Peptides
HCV NS3:1073–1081 (CINGVCWTV), HCV NS3:1406–1415
(KLVALGINAV), CMV pp65:495–503 (NLVPMVATV) were
obtained from Synthetic Biomolecules (San Diego, CA). T2 or
HepG2 cells were loaded with each peptide by incubating 1610
6
cells/ml in complete medium containing 5 mg/ml (unless other-
wise noted) of peptide at 37uc for 2 hours. Peptide-loaded cells
were washed with fresh complete medium before coculture with
responders.
TCR a and b Chain Identification
The TCR a chain from the HCV NS3-1073–1081-reactive T-
cell clone was identified by 59 RACE as previously described
[37,60]. Briefly, total RNA was isolated from 2.5610
6 cells using
TRIzol (Invitrogen), first-strand cDNA was synthesized, and the
TCR cDNAs were amplified using the SMART RACE cDNA
Amplification kit (Clontech Laboratories, Inc, Mountain View,
CA). Fragments containing random TCR a chains were amplified
using the Advantage 2 PCR Enzyme system (Clontech Labora-
tories, Inc) using the universal primer A mix and a TCR a
constant region (AC) specific reverse primer. The random PCR
products were ligated into TA PCR2.1-Topo cloning vector, and
transformed into Escherichia coli TOP 10 competent cells
(Invitrogen). Bacterial clones were screened for the presence of
TCR a chain cDNA by PCR and random 59 RACE clones were
sequenced using fluorescent dye labeled ddNTPs (Applied
Biosystems Inc, Foster City, CA). DNA sequence analysis revealed
a single productively rearranged TCR a chain which used the
AV20s1. The full-length a chain was amplified from cDNA using
an AV20s1 forward (5-AAGTCGACGTTTGCACCTAGAA-
TATGAGGCAAGTGGCG-3) and an AC reverse (5-AAGTC-
GACTCAGCTGGACCACAGCCGCAG-3) primer containing
Sal I restriction sites for subsequent subcloning. The PCR product
was ligated into the pCR 2.1 TA cloning vector (Invitrogen), and
transformed into Escherichia coli TOP 10 competent cells
(Invitrogen). Bacterial clones were screened for the presence of
the a chain cDNA via PCR and were sequenced to ensure that no
errors had occurred during PCR amplification.
The TCR b chain from the HCV-reactive T-cell clone was
identified via RT-PCR using a panel of TCR b chain V region
(BV) subfamily specific primers as previously described [37].
Briefly, total RNA was isolated and first strand cDNA was
prepared from 2.5610
6 T cells using the procedure as described
above for the a chain identification. A single band was amplified
using the BV13 subfamily specific primer and the TCR b chain
was identified as BV13s6 based on known TCR BV genomic DNA
sequences. The full-length b chain was amplified from cDNA
using a BV13s6 forward (59-CTCGAGGCACCTGCCATGAG-
CATCAGCCTC-39) and a BC2 reverse (59-AACTCGAGC-
TAGCCTCTGGAATCCTTTCTCTTGACCAT-39) primer that
each contained Xho I restriction sites for subsequent subcloning.
The PCR fragment was ligated into the pCR 2.1 TA cloning
vector, and transformed into Escherichia coli TOP 10 competent
cells. Bacterial clones were screened for the presence of the b chain
gene, and recombinant clones were sequenced to ensure that no
errors had occurred during PCR amplification.
Retroviral Vector Construction
The SAMEN CMV/SRa retroviral vector has been previously
described [14] and was used as the backbone for all retroviral
constructs. The TCR a and b chains were linked by a 2A self
cleavage peptide. The HCV TCR a chain, 2A linker and b chain
fusion gene fragment was inserted into the Xho I and Sal I
restriction sites of the retrovirus vector. The configuration of the
retroviral vector used in this study is shown in Figure 4.
Retroviral Transduction
Retroviral supernatants were prepared using a transient
transfection protocol as described [41]. Briefly, 5610
6 Plat-A cells
were plated in 10 cm poly-D-Lysine coated plates in 10 ml
DMEM containing 10% FBS without antibiotics at sufficient
density to provide 60% to 70% confluence after 24 hr. Cells were
transiently cotransfected with 9 mg of retroviral vector DNA and
4.5 mg of plasmid DNA containing the vesicular stomatitis virus
envelope gene using Lipofectamine 2000 (Invitrogen). Transfec-
tion medium was replaced with 10 ml complete medium after 6 h
incubation, and retroviral supernatants were collected after 48 hr.
Jurkat 76 were transduced by spinoculation as described [14].
Briefly, Jurkat 76 cells were resuspended at a concentration of
2610
6/ml in retroviral supernatant containing 8 mg/mL poly-
brene. 1 ml of cells was added to each well of a 24-well flat-bottom
tissue culture plate then spun for 90 min at 10006ga t3 2 uC. After
centrifugation, the cells were resuspended in their wells, incubated
for 4 hr at 37uC, and 1 mL fresh complete medium was added to
each well. This spinoculation procedure was repeated the next day
using fresh retroviral supernatant. After 24 hr, the transduced cells
were resuspended at 5610
5/ml in culture medium and transduced
cells were selected by the addition of 2 mg/mL of G418.
T cells were transduced by spinoculation as described [14].
Briefly, retrovirus was first loaded onto RetroNectin-coated 24-
well flat-bottom non-treated tissue culture plates by adding 1 mL
of fresh retroviral supernatant per well and the plates were spun
for 2 hr at 2,0006ga t3 2 uC. T cells derived from healthy donors
were activated using 50 ng/mL anti-CD3 monoclonal antibody
and 300 IU/mL rhIL-2. The activated T cells were resuspended
at 1610
6 cells/mL with culture medium supplemented with
300 IU/mL of rhIL2. The T cells were then gently added to the
plates and mixed with the viral supernatnant. The plates were
continuously centrifuged at 1,0006g for 10 min at 32uC. After
24 hours, the transduced T cells were selected by adding 1 mg/
mL of G418. The CD4
+ T cells were sorted from the TCR-
transduced T cells by positive selection with magnetic beads. The
purity of separated CD4
+ and CD8
+ cells was confirmed by FACS
analysis.
Immunofluorescence Staining
All T cell and tumor cell lines were stained for immunofluo-
rescence with fluorochrome conjugated anti-CD3 (APC), Vb13.6
(FITC), anti-CD4 (APC), anti-CD8 (FITC), anti-CD107a, (PE)
and anti-HLA-A2 (PE) purchased from BD Biosciences, San
Diego, CA. PE conjugated HCV NS3:1073–1081 or HCV
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from Proimmune Ltd., Oxford, United Kingdom. In all
experiments, 10
6 live cells were stained for 30 minutes on ice
with individual monoclonal antibodies or pentamers. Cells were
washed and stained with a second reagent or analyzed
immediately on an Accuri C6 or BD FACSCalibur flow
cytometer. The log fluorescence of a minimum of 10
6 cells was
analyzed for each sample.
Cytokine Release Assays
Antigen reactivity by the HCV-reactive T cell clones and HCV
TCR transduced cells was measured in cytokine release assays as
described [13]. Briefly, 1610
5 responder and stimulator cells were
cocultured in a 1:1 ratio in 96-well U-bottom tissue culture plates
in 200 mL complete medium. For the Jurkat 76 experiments,
10 ng/mL of PMA (Sigma-Aldrich, St. Louis, MO) was added to
each well. As a positive control for Jurkat stimulation, maximal
cytokine release was obtained by the addition of 1 mg/mL
ionomycin (Sigma-Aldrich). Cocultures were incubated at 37uC
for 20 hours, and then supernatants were harvested. The amount
of cytokine released was measured via ELISA using monoclonal
antibodies to interferon-c (Pierce, Rockford, IL) or IL-2 (R&D
Systems, Minneapolis, MN).
Intracellular Cytokine Staining
Multiparameter flow cytometry was performed using a BD
FACSCanto II instrument (BD Biosciences, San Jose, CA) and
analyzed using FACSDiva software (BD). Antibodies for cell
surface CD3, CD4 and CD8 and for intracellular IFN-c, TNF-a,
and IL-2 were purchased from BD or eBioscience (San Diego,
CA). Transduced T cell cultures were stimulated for 6 hours at
37uC in the presence of brefeldin A (Sigma-Aldrich) with equal
numbers of T2 cells that had previously been loaded with the
TCR-specific antigen (HCV-1073 peptide, 1 mg/ml) or with
another HCV-derived A2-restricted control peptide (HCV-132,
1 mg/ml). After stimulation cells were stained for surface antigens,
fixed for 30 minutes at 4uC in 100ml Fix and Perm Medium A
(Caltag, Burlingame, CA), permeabilized using 100ml Fix and
Perm Medium B (Caltag) and incubated with anti-cytokine
antibodies for 1 hour at 4uC. Cell suspensions were then washed
in PBS-BSA-Azide and fixed in 200 ml 1% PFA and acquired after
1 hour.
CD107a Expression Assay
CD107a expression was used as a surrogate marker to assess the
cytolytic ability of HCV 1073 TCR transduced T cells. HCV 1073
TCR transduced T were cocultured with a panel of stimulators
using methods similar our cytokine release assays described above.
Stimulators included T2 cells loaded with the HCV NS3:1073–
1081 or CMV pp65;495–503 and tumor targets (HepG2 and
HepG2 expressing the HCV 1073 minigene). Briefly, 1610
5
responder and stimulator cells were cocultured in a 1:1 ratio in 96-
well U-bottom tissue culture plates in 200 mL complete medium.
Cocultures were incubated at 37uC for 20 hours, and then cells
were harvested and washed. The cells were stained with anti-CD3
mAb, anti-CD8 mAb and anti-CD107a mAb (BD Pharmingen,
San Diego, CA) and were analyzed by flow cytometer. Each
histogram represents the log fluorescence of 10
4 live T cells (gated
using CD3 staining).
Supporting Information
Figure S1 HLA-A2 expression on human HCC lines. HepG2
HCC cells were used throughout this study as stimulator cells for
the HCV TCR transduced T cells. To confirm their HLA-A2
expression levels, HepG2 cells were stained with PE conjugated
anti-HLA-A2 mAb (solid curve) or and isotype control mAb (open
curve) and the amount of fluorescence staining was quantified by
flow cytometry. As staining controls, the HLA-A2 negative HCC
cell line Huh-7 and an HLA-A2 transfectant was stained. Each
histogram represents the log fluorescence of 10
4 live cells.
Found at: doi:10.1371/journal.ppat.1001018.s001 (0.08 MB TIF)
Figure S2 Pentamer staining of HCV TCR transduced T cells.
HCV TCR transduced normal PBL-derived T cells were stained
HCV peptide loaded pentamers. Two representative TCR
transduced T cell cultures (Donors 4 and 5) and a normal donor
untransduced cells (Donor 5) were stained with anti-CD4 mAb,
anti-CD8 mAb, and HLA-A2 pentamers loaded with the HCV
NS3:1073–1081 peptide. The percent pentamer positive CD8
+ T
cells (upper row) and CD4
+ T cells (lower row) is shown in each
histogram. Each histogram represents the log fluorescence of 10
4
live cells.
Found at: doi:10.1371/journal.ppat.1001018.s002 (0.23 MB TIF)
Figure S3 Cytokine production by HCV TCR 1073-transduced
T cells. PBMC from two normal donors (donors 4 and 5) were
transduced to express the HCV TCR 1073 and were assessed for
cytokine secretion. T2 cells were pulsed for 2 hr with 5 mg/ml of
the HCV NS3 1073–1081 peptide or the CMV pp65 control
peptide. Peptide-pulsed T2 cells, HepG2 cells and HCV
+ HepG2
cells were cocultured for 20 hr in microwells with the HCV TCR
1073 T cells. The production of IFN-c and IL-2 were measured by
ELISA.
Found at: doi:10.1371/journal.ppat.1001018.s003 (0.06 MB TIF)
Figure S4 Relative avidity of HCV TCR 1073-transduced T
cells. The functional avidity of HCV TCR transduced PBL-
derived normal T cells was compared to the parent HCV
NS3:1073:1081 T cell clone using interferon-c release assays. T2
cells were loaded for 2 hr with varied concentrations of HCV NS3
1073–1081 peptide (0.01–1000 nM). These peptide-loaded T2
cells were cocultured for 20 hr in microwells with three different
HCV TCR transduced T cell cultures or the parent HCV 1073-
reactive T cell clone. The amount of interferon-c produced was
measured by ELISA.
Found at: doi:10.1371/journal.ppat.1001018.s004 (0.06 MB TIF)
Acknowledgments
The authors wish to thank Ms. Mingli Li for technical assistance. The
authors are grateful to the MUSC Center for Cellular Therapy for their
invaluable support. Plat-A cells were kindly provided by Dr. Toshio
Kitamura.
Author Contributions
Conceived and designed the experiments: YZ MGH MIN. Performed the
experiments: YZ YL KMM MGH TL. Analyzed the data: YZ KMM
MIN. Contributed reagents/materials/analysis tools: YZ LGM MGH
MHMH HRR. Wrote the paper: YZ HRR MIN.
References
1. National Centers for Disease Control and Prevention.Hepatitis C Fact Sheet,
http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact/html.
2. World Health Organization (2000) Hepatitis C – Global Surveillance Update.
Weekly Epidemiological Record 75: 17–28.
Transduction of T Cells with HCV-Specific TCR
PLoS Pathogens | www.plospathogens.org 11 July 2010 | Volume 6 | Issue 7 | e10010183. Centers for Disease Control and Prevention Web site on Hepatitis C: http://
www.cdc.gov/.
4. Scientific Registry of Transplant Recipients (SRTR): OPTN/SRTR Annual
report: transplant data 1993–2002. (Chapter VII). Available: www.ustransplant
org. 2003.
5. Adam R, McMaster P, O’Grady JG, Castaing D, Klempnauer JL, et al. (2003)
European Liver Transplant Association. Liver Transpl. 1231 p.
6. McHutchison JG, Fried MW (2003) Current therapy for hepatitis C: pegylated
interferon and ribavirin. Clin Liver Dis 7: 149–161.
7. Rehermann B (2000) Interaction between the hepatitis C virus and the immune
system. Semin Liver Dis 20: 127–141.
8. Missale GR, Bertoni V, Lamonaca A, Valli M, Massari C, et al. (1996) Different
clinical behaviors of acute hepatitis C virus infection are associated with different
vigor of the anti-viral cell-mediated immune response. J Clin Invest 98: 706–714.
9. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Chisari.
Determinants of viral clearance and persistence during acute hepatitis C virus
infection. J Exp Med 194: 1395–1406.
10. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, et al. (2004)
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest
114: 250–259.
11. Pavio N, Lai MM (2003) The hepatitis C virus persistence: how to evade the
immune system? J Biosci 28: 287–304.
12. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, et al. (2005) Immune
evasion versus recovery following acute hepatitis c virus infection from a shared
source. J Exp Med 201: 1725–1731.
13. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, et al. (1995)
Characterization of the functional specificity of a cloned T-cell receptor
heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 55:
748–52.
14. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA (1999) and Nishimura M.
I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood
lymphocytes confers anti-tumor reactivity. J Immunol 163: 507–513.
15. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI (2001) Retroviral
transduction of a T cell receptor specific for an Epstein- Barr virus-encoded
peptide. Clin Immunol 98: 220–228.
16. Heemskerk HMH, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JF
(2002) Redirection towards anti-leukemic reactivity of CMV specific peripheral
T lymphocytes using T cell receptor gene transfer. Blood 100: 218A–219A.
17. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders W, et al.
(2003) Transfer of TCR Genes into Mature T Cells Is Accompanied by the
Maintenance of Parental T Cell Avidity. J Immunol 170: 1209–1217.
18. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, et al. (2001)
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR
gene transfer. Nat Immunol 2: 962–970.
19. Ueno TH, Tomiyama M, Fujiwara S, Takiguchi M (2004) Functionally
impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions.
J Immunol 173: 5451–5457.
20. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, et al. (2005)
Preservation and redirection of HPV16E7-specific T cell receptors for
immunotherapy of cervical cancer. Clin Immunol 114: 119–129.
21. van der Veken LT, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JH,
et al. (2005) HLA class II restricted T-cell receptor gene transfer generates
CD4(+) T cells with helper activity as well cytotoxic capacity. Gene Ther 12:
1686–95.
22. Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, et al. (2005)
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells
by cell engineering with tumor peptide–specific T-cell receptor genes. Blood 106:
470–476.
23. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, et al.
(2005) Redirecting human T lymphocytes toward renal cell carcinoma specificity
by retroviral transfer of T cells receptor genes. Hum Gene Ther 16: 799–810.
24. Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, et al. (2006)
Identification of a CD8-Independent Hepatitis C Virus-Specific T Cell Receptor
That Does Not Require CD8 For Target Cell Recognition. Hepatology 43:
973–81.
25. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, et al. (2007) High-
affinity TCRs generated by phage display provide CD4+ T cells with the ability
to recognize and kill tumor cell lines. J Immunol 179: 5845–54.
26. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, et al. (2005) Elimination of
human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced
human T cells. Blood 106: 3062–7.
27. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, et al. (2008)
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell
receptor. Nat Med 14: 1390–5.
28. Dossett ML, Teague RM, Schmitt TM, Tan X, Cooper LJ, et al. (2009)
Adoptive Immunotherapy of Disseminated Leukemia With TCR-transduced,
CD8(+) T Cells Expressing a Known Endogenous TCR. Mol Ther 17: 742–9.
29. Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, et al. (2006)
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-
A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Clin Cancer Res 12: 1229–36.
30. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006)
Cancer regression in patients after transfer of genetically engineered lympho-
cytes. Science 314: 126–9.
31. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, et al. (2009) Gene
therapy with human and mouse T-cell receptors mediates cancer regression and
targets normal tissues expressing cognate antigen. Blood 2009 114: 535–46.
32. Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, et al.
(2004) Cutting Edge: Identification of Hepatitis C Virus-Specific CD8+ T Cells
Restricted by Donor HLA Alleles following Liver Transplantation. J Immunol
173: 5355–5359.
33. Rehermann B (2009) Hepatitis C virus versus innate and adaptive immune
responses: a tale of coevolution and coexistence. J Clin Invest 119: 1745–54.
34. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B (2001)
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-
specific cytotoxic T cells. J Virol 75: 11392–400.
35. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S,
Sette A, Chisari FV (1997) Immunological significance of cytotoxic T
lymphocyte epitope variants in patients chronically infected by the hepatitis C
virus. J Clin Invest 100: 2376–85.
36. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, et al. (1994)
T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-
infiltrating lymphocyte lines. Proc Natl Acad Sci 91: 2829–2833.
37. Nishimura MI, YKawakami P, Charmley B, O’Neil J, Shilyansky JR, et al.
(1994) T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of
melanoma-specific long-term lines. J Immunother 16: 85–94.
38. Lyons GE, Roszkowski JJ, Mann S, Yee C, Kast WM, et al. (2006) TCR
Tetramer Binding and the Lack There of Does Not Necessitate Antigen
Reactivity in TCR Transduced T Cells. Cancer. Immunol Immunother 55:
1142–50.
39. Lyons GE, Moore T, Brasic N, Li M, Roszkowski JJ, et al. (2006) Influence of
Human CD8 on Antigen Recognition by TCR Transduced Cells. Cancer Res
66: 11455–61.
40. Morgan RA, Dudley ME, Yu YYL, Zheng Z, et al. (2003) High Efficiency TCR
Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of
Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the
Recognition of Autologous Melanoma Antigens. J Immunol 171: 3287–95.
41. Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, et al. (2003)
CD8-independent tumor cell recognition is a property of the T cell receptor and
not the T cell. J Immunol 170: 2582–9.
42. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, et al. (2005)
Simultaneous Generation of CD8
+ and CD4
+ Melanoma Reactive T Cells By
Retroviral Mediated TCR Gene Transfer. Cancer Res 65: 1570–1576.
43. Heller KN, Gurer C, Mu ¨nz C (2006) Virus-specific CD4+ T cells: ready for
direct attack. J Exp Med 203: 805–8.
44. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of
high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive
immunotherapy. Proc Natl Acad Sci U S A 93: 4102–7.
45. Zeh HJ, 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999) High
avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo
antitumor efficacy. J Immunol 162: 989–94.
46. Hofmann M, Radsak M, Rechtsteiner G, Wiemann K, Gu ¨nder M, et al. (2004)
T cell avidity determines the level of CTL activation. Eur J Immunol 34:
1798–806.
47. Slifka MK, Whitton JL (2001) Functional avidity maturation of CD8(+) T cells
without selection of higher affinity TCR. Nat Immunol 2: 711–7.
48. Holler PD, Lim AR, Cho BK, Rund LA, Kranz DM (2001) CD8(2) T cell
transfectants that express a high affinity T cell receptor exhibit enhanced
peptide-dependent activation. J Exp Med 194: 1043–52.
49. Holler PD, Kranz DM (2003) Quantitative analysis of the contribution of TCR/
pepMHC affinity and CD8 to T cell activation. Immunity 18: 255–64.
50. Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, et al. (2009)
Relationship between CD8-dependent antigen recognition, T cell functional
avidity, and tumor cell recognition. Cancer Immunol Immunother 58: 719–28.
51. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006)
CD4
+ T-cell memory: generation and multi-faceted roles for CD4
+ T cell in
protective immunity to influenza. Immunol Rev 211: 8–22.
52. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, et al. (2006) Cytotoxic
CD4 T cells in viral hepatitis. J Viral Hepat 13: 505–14.
53. Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, et al. (2003) A
MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated
from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171:
219–25.
54. Heemskerk MH, Hoogeboom M, Hagedoom R, Kester MG, Willemze R, et al.
(2004) Reprogramming of virus-specific T cells into leukemia-reactive T cells
using T cell receptor gene transfer. J Exp Med 199: 885–894.
55. Langerman A, Callendar GG, Nishimura MI (2004) Engineering Bifunctional T
Cells as a Treatment for Immunotherapy Resistant Tumors. J Trans Med 2: 42.
56. Weinhold M, Sommermeyer D, Uckert W, Blankenstein T (2007) Dual T cell
receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit
tumor growth without causing severe autoimmunity. J Immunol 179:
5534–5542.
57. Sobesky R, Feray C, Rimlinger F, Derian N, Dos Santos A, et al. (2007) Distinct
hepatitis C virus core and F protein quasispecies in tumoral and nontumoral
hepatocytes isolated via microdissection. Hepatology 46: 1704–1712.
58. Mommaas B, van Halteren AGS, Pool J, van der Veken L, Wieles B, et al. (2005)
Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell
receptor gene transfer. Haematologica 90: 1415–1421.
Transduction of T Cells with HCV-Specific TCR
PLoS Pathogens | www.plospathogens.org 12 July 2010 | Volume 6 | Issue 7 | e100101859. Morita S, Kojima T, Kitamura T (2000) Plat-E: an efficient and stable system for
transient packaging of retroviruses. Gene Therapy 7: 1063–1066.
60. Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, et al. (2000) Functional
reconstitution of Class-II MHC-restricted T cell immunity mediated by
retroviral transfer of the abTCR complex. J Immunol 165: 528–533.
61. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995)
Reconstitution of cellular immunity against cytomegalovirus in recipients of
allogeneicbonemarrow by transfer ofT-cellclonesfrom thedonor.N Engl JMed
333: 1038–1044.
Transduction of T Cells with HCV-Specific TCR
PLoS Pathogens | www.plospathogens.org 13 July 2010 | Volume 6 | Issue 7 | e1001018